For how we live.
A 411,000-patient claims study found adults on GLP-1 drugs who started oxycodone had more severe constipation and bowel obstruction at 30 days than those starting hydrocodone or tramadol.
In 69 people across normal weight, overweight and type 2 diabetes, a stevia drink behaved like water — no shift in glucose, insulin, gut hormones, appetite or how much they ate next.
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
Matched against DPP-4 inhibitors, GLP-1 users had slightly more diabetic retinopathy and more retinopathy procedures. Vision impairment and blindness did not differ — and the coding for those is poor.
A Lancet series covering 135 million person-years found the largest risk reductions in that range. Trials of isolated fibre supplements produce much smaller effects on much narrower outcomes.
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.
A 1.5-million-person records study reports lower mortality with GLP-1 drugs than with SGLT2 inhibitors, and the largest absolute gains in people with serious mental illness. The design cannot prove it.
A sibling-controlled cohort of 1.1 million men, a genetic analysis of 712 traits and a UK Biobank study of fitness change converge — and they agree on where the exception is.
Across 89,573 accelerometer-monitored adults and 678 conditions, no disease showed a significant difference between activity concentrated in one or two days and activity spread through the week.
Two WHO bodies reported on the same day in July 2023 and reached findings that sound contradictory. Both were right, because they were answering different questions.
A 2025 meta-analysis of 57 studies found the mortality curve bending at about 7,000 steps a day. The 10,000 figure traces to the trade name of a Japanese step counter sold in 1965.
In February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
Tirzepatide and semaglutide showed comparable psychiatric risk profiles against each other over two years. Against earlier GLP-1 drugs, semaglutide came out ahead on all three measures.
Lilly's oral GLP-1 pill actually lowered liver enzymes on average, and its rate of serious liver-injury criteria matched placebo exactly — six cases in each group, none attributable to the drug.
Pooling 2,906 participants, researchers ranked how antidiabetic drugs affect fat versus lean body mass. Exercise blunted liraglutide's muscle loss; metformin, insulin, and DPP4 inhibitors barely moved either measure.
After 12 months, HbA1c was 6.5% among people managed by community health workers versus 7.1% among those referred to clinics. With 103 participants analysed, the confidence interval crosses zero.
The ESC Atlas reports 68 million disability-adjusted life years and more than three million cardiovascular deaths a year, with middle-income countries carrying roughly double the mortality of high-income ones.
The LiverScreen project ran transient elastography across nine countries, then sent everyone who screened positive to a hepatologist. The gap between the two numbers is the interesting part.
Awiqli's approval for adults with type 2 diabetes rests on four trials comparing it with daily basal insulin. A pediatric dosing study is still due by June.
A survey-based analysis of the European Health Interview Survey puts a price on Europe's obesity-related hospital use, and finds the strongest single association is not with obesity at all.
Pooling 94 cohort studies, grip strength tracked with later dementia, depression and disability. The authors rate their own confidence in the numbers as limited to moderate.
Compared with a diabetes drug from another class, GLP-1 agonists were followed by fewer new diagnoses of alcohol, opioid, nicotine and other substance use disorders.
ACHIEVE-3 randomised 1,698 people to orforglipron or oral semaglutide for 52 weeks. Orforglipron cut HbA1c more at every dose comparison — and produced more side effects and more dropouts.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
In a 618-person randomized trial, 27.8% of the intervention group met the sustained-remission endpoint at 24 months against 21.2% of comparators. The confidence interval nearly touches no effect.
Large taxed beverage sales fell 24 to 31 percent under the tax. In the period after repeal they remained 13 to 24 percent below pre-tax levels — and prices stayed elevated too.
A December survey found getting stronger is the leading 2026 health goal. The best meta-analysis of muscle-strengthening and mortality finds a benefit that plateaus at around 30 to 60 minutes a week.
Matched against a comparator diabetes drug, incretin agonists were associated with an 8% lower rate of CPAP procedures — alongside a 32% lower mortality that should make readers cautious.
A UK Biobank analysis of 96,365 people found a dose-response relationship between lifetime night-shift exposure and cardiovascular-kidney-metabolic disease — amplified in those who also slept short.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
Two November burden analyses put diabetes diagnosed before 40 on an upward path to 2050. In the Americas, Central Latin America carried the highest rates and men carried more of the burden than women.
In ATTAIN-2, the highest dose of the oral GLP-1 pill cut body weight 9.6% over 72 weeks in adults with type 2 diabetes, against 11.2% in the earlier trial of adults without diabetes.
The 27 recommendations cover monitoring, diet and medication for type 1, type 2 and gestational diabetes. WHO had guidance on diabetes and guidance on pregnancy, but never on the two together.
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.
VESALIUS-CV randomised 12,257 patients with atherosclerosis or diabetes but no prior MI or stroke. Evolocumab reduced the three-point event rate from 8.0% to 6.2% over a median 4.6 years.
SURPASS-CN-INS randomised 257 adults at 26 Chinese hospitals. The 10 mg and 15 mg doses performed almost identically against placebo, and diarrhoea affected roughly a third of those on the higher doses.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.
A pooled analysis of 72,776 Korean adults found an 11% higher type 2 diabetes risk in the top intake quartile. An updated meta-analysis of 17 cohorts put the dose-response at 10% per 10% of intake.
Two phase 3b trials tested semaglutide 7.2 mg against the approved 2.4 mg dose. The extra weight loss was real but modest, and gastrointestinal side-effects and dysaesthesia rose alongside it.
A Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
Dapagliflozin beat placebo on liver histology over 48 weeks in six Chinese hospitals. Weeks later, European regulators recommended the first purpose-built drug for the same disease.